Veru (NASDAQ:VERU) stock is taking off on Monday as investors react to recent news about the company’s Covid-19 treatment.
The big news here is the mortality rate of Covid-19 patients treated with sabizabulin as compared to those in a placebo group. The Phase 3 clinical trial reported a 20% mortality rate for those taking sabizabulin, as compared to a 45% mortality rate for those in the placebo group.
In addition to this, Veru reported that sabizabulin 9 mg was well tolerated during the Phase 3 clinical trial.
This post originally appeared at InvestorPlace.